Improving availability and affordability of plasma-derived medicines

Biologicals

Volumn 38, Issue 1, 2010, Pages 81-86

  Cheraghali, Abdol Majid ^a   Abolghasemi, Hassan ^a,b  

^a IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Affordability; Availability; Plasma fractionation; Plasma derived medicines

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; COMPLEMENT COMPONENT C1S INHIBITOR; FIBRIN GLUE; FIBRINOGEN; IMMUNOGLOBULIN; PLASMA PROTEIN; PROTEIN C; PROTHROMBIN COMPLEX; THROMBIN; VON WILLEBRAND FACTOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; DERMATOMYOSITIS; DEVELOPING COUNTRY; DRUG MARKETING; DRUG SYNTHESIS; ERYTHROCYTE APLASIA; HEALTH CARE COST; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE SCLEROSIS; NEUTROPENIA; PEMPHIGOID; PLASMA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VON WILLEBRAND DISEASE;

DEVELOPING COUNTRIES; DRUG UTILIZATION; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IRAN; PHARMACEUTICAL PREPARATIONS; PLASMA;

EID: 77649180333     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2009.10.004     Document Type: Article

References (24)

1. Burnouf T. Modern plasma fractionation. Transfusion Medicine Review 21 (2007) 101-117
2. Tencer T., Friedman H.S., Li-McLeod J., and Johnson K. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection. Journal of Managed Care Pharmacy 13 (2007) 790-798
3. Rajnish K.J., Chakravorty N., Chakravorty D., Bhattacharya P.K., Yadava A., and Agarwal R.C. Albumin: an overview of its place in current clinical practice. Indian Journal of Anaesthesia 48 (2004) 433-436
4. Maggie M.C., Thomas W., Whitman L., Kahwash E., Dolan S., Smith S., et al. Intravenous immunoglobulin utilization in the Canadian Atlantic Provinces. Transfusion 47 (2007) 207-280
5. Teckman J.H., and Lindblad D. Alpha-1-antitrypsin deficiency: diagnosis, pathophysiology, and management. Current Gastroenterology Reports 8 (2006) 14-20
6. The Marketing Research Bureau Inc., 2007. The Worldwide plasma fractionation market; 2006.
7. Skinner MW. Optimizing access to coagulation factors. International Plasma Protein Congress; 3-4 March, 2009, Paris.
8. Burnouf T. Plasma fractionation in the world: current status. Transfusion Clinique et Biologique 14 (2007) 41-50
9. O'Mahony B. Future plasma requirements. International Plasma Protein Congress; 3-4 March, 2009, Paris.
10. Farrugia A. Product delivery in the developing world: options, opportunities and threats. Haemophilia 10 Suppl. 4 (2004) 77-82
11. World Federation of Hemophilia Report on the Annual Global Survey 2006; Dec 2007. http://www.wfh.org/2/7/7_0_Link7_GlobalSurvey2006.htm.
12. Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia 7 (2001) 117-122
13. Farrugia A., Evers T., Falcou P.F., Burnouf T., Amorim L., and Thomas S. Plasma fractionation issues. Biologicals 37 (2009) 88-93
14. Cheraghali A.M., and Abolghasemi H. Plasma fractionation a useful mean to improve national transfusion system and blood safety: Iran experience. Haemophilia 15 (2009) 487-493
15. WFH, Contract Fractionation; 2004. www.wfh.org/2/docs/Publications/Treatment_Products/Monographs/FF-5_English_Fractionation.pdf.
16. WHO, Information sheet, Plasma contract fractionation program. http://www.who.int/bloodproducts/publications/en/Infosheet_plasma_contract_fractionation.pdf.
17. Flesland O., Seghatchian J., and Solheim B.G. The Norwegian plasma fractionation project - a 12 year clinical and economic success story. Transfusion Apheresis Science 28 (2003) 93-100
18. Cheraghali A.M., and Aboofazeli R. Economical impact of plasma fractionation project in Iran on affordability of plasma derived medicines. Transfusion Medicine 19 (2009) 363-368
19. Bird A., Isarangkura P., Almagro D., Gonzaga A., and Srivastava A. Factor concentrates for haemophilia in the developing world. Haemophilia 4 (1998) 481-485
20. Sher GD. Plasma self-sufficiency: the evolving Canadian perspective. International Plasma Protein Congress; 3-4 March, 2009, Paris.
21. Flood P, Wills P, Lawler P, Ryan G, Rickard KA. Review of Australia's Plasma Fractionation Arrangements; 2006. http://www.health.gov.au/plasmafractionationreview.
22. Cheraghali A.M. Availability of blood components and plasma derived medicines in Iran. Transfusion and Apheresis Science 37 (2007) 3-7
23. Cheraghali A.M. Iran pharmaceutical market. Iranian Journal of Pharmaceutical Research 5 (2006) 1-7
24. Abolghasemi H., Maghsudlu M., Amini Kafi-Abad S., and Cheraghali A.M. Introduction to Iranian Blood Transfusion Organization and blood safety in Iran. Iranian Journal of Public Health 38 Suppl. 1 (2009) 82-87